Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Julie Gaye"'
Autor:
Veronique Debien, Virginie ADAM, Rafael Caparica, Debora Fumagalli, Chloé Velghe, Julie Gaye, Vanessa Correia De Nobrega, Amal Arahmani, Gabriele Zoppoli, Martine J. Piccart-Gebhart
Publikováno v:
Journal of Clinical Oncology. 40:TPS621-TPS621
TPS621 Background: Human Epidermal growth factor Receptor-2 positive (HER2+) breast cancer (BC) heterogeneity can be captured at the mRNA level by the PAM50 classification. The HER2 “Enriched” (HER2-E) intrinsic subtype is encountered more often
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8086e5418888a60c713c10fa937dcdb
https://doi.org/10.1200/jco.2022.40.16_suppl.tps621
https://doi.org/10.1200/jco.2022.40.16_suppl.tps621
Autor:
Otto S. Hoekstra, Ahmad Awada, Patrick Flamen, Camilo Garcia, Lieveke Ameye, Sigrid Stroobants, Adrienne H. Brouwers, Carolien P. Schröder, Elisabeth G.E. de Vries, Philippe Aftimos, Laetitia E. Lamberts, Geraldine Gebhart, Catharina Wilhelmina Menke, Julie Gaye, Zena Wimana, Thomas Guiot, Manon T. Huizing, G.A.M.S. (Guus) van Dongen, Jolien Tol, Wim J.G. Oyen
Publikováno v:
ResearcherID
11001 Background: So far, no biomarker beyond HER2 status by immunohistochemistry (IHC) or in situ hybridization (ISH), has been validated to predict treatment efficacy of T-DM1, a novel antibody-d...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8093d3cbdaa9f77bbc4404effeec7c37
https://doi.org/10.1200/jco.2014.32.15_suppl.11001
https://doi.org/10.1200/jco.2014.32.15_suppl.11001